Biotech
ARTBIO Strengthens Leadership with Strategic Board Appointments to Advance Cancer Therapies
ARTBIO enhances its board with four industry veterans to propel its innovative alpha radioligand therapies, marking a pivotal step in its mission to revolutionize cancer treatment.
EnPlusOne Biosciences Aims to Revolutionize RNA Therapeutics with Enzymatic Synthesis
EnPlusOne Biosciences, under the leadership of CEO Clare Murray Ph.D., is pioneering an enzymatic approach to RNA synthesis, addressing the limitations of current methods and paving the way for scalable, pure, and environmentally friendly RNA therapeutics.
XOMA Royalty to Acquire LAVA Therapeutics in a Deal Worth Up to $1.24 Per Share Plus Contingent Value Rights
XOMA Royalty Corporation's acquisition of LAVA Therapeutics for up to $1.24 per share plus contingent value rights marks a significant move in the biotech sector, promising to benefit shareholders and advance innovative cancer treatments.
Soligenix Inc. Achieves Significant Milestone in Phase 2a Study for Behçet’s Disease Treatment
Soligenix Inc. reports promising results from its Phase 2a study of SGX945 for Behçet’s Disease, showing potential to address unmet medical needs in inflammatory conditions.
Branded Legacy, Inc. to Acquire Bio-Legacy Evaluative Group, Expanding into Intranasal Drug Delivery Market
Branded Legacy, Inc. (OTC: BLEG) has signed a Letter of Intent to acquire Bio-Legacy Evaluative Group, marking a strategic expansion into the intranasal drug delivery sector with a focus on addiction treatments and vaccine accessibility.
Fifty 1 Labs, Inc. (OTC: FITY) Showcases AI-Driven Growth Strategy in Virtual Shareholder Teleconference
Fifty 1 Labs, Inc. (OTC: FITY) highlighted its AI-driven strategy for the functional medicine and biotech sectors during a virtual teleconference, emphasizing significant market opportunities and shareholder value creation.
Fifty 1 Labs and UAV Corp to Host Virtual Shareholder Teleconference with Nobel Laureate Dr. James Orbinski
Fifty 1 Labs and UAV Corp announce a virtual shareholder teleconference featuring Nobel Laureate Dr. James Orbinski, highlighting strategic initiatives in AI-driven health solutions and biotech acquisitions.
ABVC BioPharma Achieves $100,000 Licensing Milestone with ForSeeCon, Enhancing Ophthalmology Focus
ABVC BioPharma's recent $100,000 milestone payment from ForSeeCon Eye Corporation underscores the growing commercial interest in its ophthalmology solutions, particularly Vitargus®, and strengthens its position in the global eye care market.
Nutriband Inc. Added to Four Russell Indexes, Highlighting Market Recognition and Growth Potential
Nutriband Inc.'s inclusion in four Russell indexes underscores the market's recognition of its AVERSA pipeline and its potential impact on the pharmaceutical industry.
Scinai Immunotherapeutics Ltd. Highlights PC111 Breakthrough Following Top Italian Dermatology Award
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) celebrates Dr. Roberta Lotti's award-winning research on PC111, a promising treatment for pemphigus vulgaris, underscoring its potential as a non-immunosuppressive therapy for autoimmune skin conditions.
Nutriband Inc. (NASDAQ: NTRB) Sees Price Target Increase to $15 After AVERSA Fentanyl Manufacturing Achievement
Nutriband Inc.'s price target was raised to $15 following the successful commercial manufacturing and scale-up of its AVERSA Fentanyl abuse-deterrent transdermal patch, marking a significant step towards clinical trials and potential market entry.
PolyPid Secures $26.7 Million Funding, Advances Toward FDA Approval with Promising D-PLEX₁₀₀
PolyPid Ltd. has secured $26.7 million in funding following successful Phase 3 trial results for its surgical infection prevention technology, D-PLEX₁₀₀, positioning the company for FDA approval and significant market impact.
Stonegate Capital Partners Initiates Coverage on Cingulate Inc. with Focus on ADHD Treatment Innovation
Stonegate Capital Partners has begun coverage on Cingulate Inc., highlighting the company's progress with CTx-1301, a potential breakthrough in ADHD treatment, targeting a significant market opportunity.
Medicus Pharma Ltd. (NASDAQ: MDCX) Strategically Positions Itself in the Rapidly Growing $5 Trillion Biotech Market
Medicus Pharma Ltd. is leveraging the aging global population and technological advancements in biopharma to address chronic diseases, positioning itself for significant growth in the $5 trillion biotech market by 2034.
Aditxt Inc. Strengthens Board with Appointment of Evofem CEO Saundra Pelletier
Aditxt Inc. (NASDAQ: ADTX) has appointed Saundra Pelletier, CEO of Evofem Biosciences, to its Board of Directors, signaling a strategic focus on women's health and commercialization efforts.
Scinai Immunotherapeutics Clears Italian Regulatory Hurdle for Pincell Acquisition
Scinai Immunotherapeutics Ltd. has received Italian regulatory approval to proceed with its option to acquire Pincell S.r.l., a move that could significantly expand its inflammation and immunology pipeline with Pincell's promising monoclonal antibody, PC111.
Catalio Capital Invests in $130 Million Series B Funding for GlycoEra to Advance Autoimmune Disease Treatments
Catalio Capital Management has participated in a $130 million Series B funding round for GlycoEra AG, a Swiss biotech firm, to develop innovative treatments for autoimmune diseases, marking a significant step forward in life sciences investment and healthcare innovation.
GlycoEra Secures $130 Million in Series B Funding to Advance Autoimmune Disease Treatments
GlycoEra AG, a Swiss biotech firm, has raised $130 million in a Series B funding round led by Novo Holdings, with participation from several new and existing investors, to advance its innovative treatments for autoimmune diseases.
Tenpoint Therapeutics Strengthens Leadership Team with Appointment of Melissa Epperly as CFO
Tenpoint Therapeutics appoints Melissa Epperly as CFO to lead financial strategy and operations, marking a pivotal step towards the potential U.S. launch of its innovative treatment for presbyopia, BRIMOCHOLPF.
Nutriband Reports Record Q1 Revenue, Advances Abuse-Deterrent Fentanyl Patch Development
Nutriband Inc. reported a 63% year-over-year revenue increase in Q1, driven by expanded kinesiology tape production and retail presence, while simultaneously progressing its AVERSA Fentanyl patch development through a strategic partnership with Kindeva Drug Delivery.
Scinai Immunotherapeutics Reports Revenue Growth and Narrowing Losses in Q1 2025
Scinai Immunotherapeutics demonstrates financial resilience with increased revenue from CDMO contracts and reduced net losses, signaling potential strategic pivots in its business model.
SeaStar Medical Expands Acute Kidney Injury Treatment Strategy with Promising Q1 Performance
SeaStar Medical reports significant growth in pediatric acute kidney injury treatment QUELIMMUNE and advances plans to enter the larger adult market, with potential to address a $4.5 billion annual opportunity.
Aditxt Terminates Acquisition Agreement with Appili Therapeutics
Aditxt Inc. has decided to end its planned acquisition of Appili Therapeutics, citing a lack of strategic alignment. The termination highlights potential challenges in healthcare innovation partnerships.
Tonix Pharmaceuticals Advances Fibromyalgia Drug, Reports Q1 Financial Results
Tonix Pharmaceuticals is poised for potential FDA approval of TNX-102 SL, a novel non-opioid fibromyalgia treatment, while maintaining a robust research pipeline and strong cash position. The drug could represent a significant breakthrough in fibromyalgia treatment after more than 15 years without a new drug class.
TransCode Therapeutics Implements 1-for-28 Reverse Stock Split to Maintain Nasdaq Compliance
TransCode Therapeutics will execute a reverse stock split to increase its per-share price and meet Nasdaq listing requirements, reducing outstanding shares from 23.3 million to approximately 833,620.
NanoViricides to Present at D. Boral Capital Inaugural Global Conference, Highlighting Antiviral Drug Development
NanoViricides, a clinical-stage biotech company specializing in nanomedicine-based antiviral treatments, will participate in the D. Boral Capital Inaugural Global Conference, offering investors insights into its advanced drug candidates targeting respiratory viral infections and other diseases.
NeuroSense Advances Promising ALS Treatment with Potential Global Partnership
Biotech company NeuroSense Therapeutics is in advanced discussions for a pharmaceutical partnership that could accelerate its innovative ALS treatment PrimeC, demonstrating significant survival improvements in clinical trials.
NeuroSense's ALS Drug PrimeC Shows Promise with 58% Survival Improvement, Pharmaceutical Partnership Imminent
NeuroSense Therapeutics' experimental ALS treatment PrimeC demonstrates significant potential in clinical trials, with the company positioned for a major pharmaceutical partnership and potential breakthrough in neurodegenerative disease treatment.
Quantum BioPharma Announces Corporate Updates and Debt Settlement Strategy
Quantum BioPharma Ltd. has granted restricted share units and approved debt settlement through share issuance, signaling strategic financial maneuvering and potential investment opportunities in the biotech sector.